NEW YORK – Esya Labs said Wednesday that it has partnered with Alamar Biosciences to help detect and quantify biomarkers for neurological, inflammatory, and neurodegenerative diseases.
Under the terms of the agreement, Dallas-based Esya will be a certified service provider for Alamar, combining its lysosomal biology and biomarker discovery capabilities and machine learning-driven diagnostics with Alamar's NULISA (nucleic acid linked immuno-sandwich assay) proteomics platform and Argo HT System. These will be made available to pharmaceutical companies developing therapeutics for diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis (ALS).
Financial and other terms of the collaboration were not disclosed.
"By integrating Esya's cutting-edge platforms with Alamar’s innovative assay systems, we're poised to deliver transformative tools for addressing the challenges of neurodegenerative diseases," Esya Labs CEO Dhivya Venkat said in a statement.
Alamar Biosciences has inked several other partnerships throughout 2024. Early in the year, it partnered with Biognosys to jointly pursue research in plasma proteomics and later partnered with ADx NeuroSciences and the Michael J. Fox Foundation.